mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary

S Mabuchi, C Kawase, DA Altomare, K Morishige… - Clinical Cancer …, 2009 - AACR
Purpose: Mammalian target of rapamycin (mTOR) plays a central role in cell proliferation
and is regarded as a promising target in cancer therapy, including for ovarian cancer. This …

Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary

S Mabuchi, C Kawase, DA Altomare, K Morishige… - Molecular cancer …, 2010 - AACR
This study examines the role of vascular endothelial growth factor (VEGF) as a therapeutic
target in clear cell carcinoma (CCC) of the ovary, which has been regarded as a …

Prognostic factors for survival in patients with recurrent cervical cancer previously treated with radiotherapy

S Mabuchi, F Isohashi, Y Yoshioka, K Temma… - International Journal of …, 2010 - ijgc.bmj.com
Introduction: The aim of this study was to identify the prognostic factors and to establish a
model for the prediction of life expectancy in patients with recurrent cervical cancer that had …

The activity of carboplatin and paclitaxel for recurrent cervical cancer after definitive radiotherapy

S Mabuchi, K Morishige, M Fujita, T Tsutsui… - Gynecologic …, 2009 - Elsevier
OBJECTIVES: The aim of this study was to evaluate the efficacy of paclitaxel–carboplatin
(TC) for recurrent cervical cancer after definitive radiotherapy and to compare the results …

Concurrent weekly nedaplatin, external beam radiotherapy and high-dose-rate brachytherapy in patients with FIGO stage IIIb cervical cancer: a comparison with a …

S Mabuchi, H Ugaki, F Isohashi, Y Yoshioka… - Gynecologic and …, 2010 - karger.com
Objectives: The aim of this study was to evaluate whether nedaplatin-based concurrent
chemoradiotherapy (CCRT) using high-dose-rate intracavitary brachytherapy (HDR-ICBT) is …

Postoperative whole pelvic radiotherapy plus concurrent chemotherapy versus extended-field irradiation for early-stage cervical cancer patients with multiple pelvic …

S Mabuchi, M Okazawa, F Isohashi, Y Ohta… - Gynecologic …, 2011 - Elsevier
OBJECTIVES: The aim of this study was to compare the efficacy of postoperative pelvic
radiotherapy plus concurrent chemotherapy with that of extended-field irradiation (EFRT) in …

[HTML][HTML] Carboplatin and paclitaxel as an initial treatment in patients with stage IVb cervical cancer: a report of 7 cases and a review of the literature

S Mabuchi, K Morishige, T Enomoto… - Journal of Gynecologic …, 2010 - ncbi.nlm.nih.gov
Objective The aim of this study is to evaluate the efficacy of carboplatin-paclitaxel (TC) as an
initial treatment in patients with the International Federation of Gynecology and Obstetrics …

The first 2 cases of granulocyte colony-stimulating factor producing adenocarcinoma of the uterine cervix

S Mabuchi, Y Matsumoto, E Morii… - International journal …, 2010 - journals.lww.com
Granulocyte colony-stimulating factor (G-CSF)-producing nonhematopoietic malignancies
have been reported in various organs, and most of them have been associated with poor …

Use of monoclonal antibodies in the treatment of ovarian cancer

S Mabuchi, K Morishige, T Kimura - Current Opinion in Obstetrics …, 2010 - journals.lww.com
As mAbs selectively target tumor cells expressing tumor-associated antigens, mAb-based
therapy may offer potential benefits such as avoiding the cytotoxic side effects on normal …

Participation of JAK, STAT and unknown proteins in human placental lactogen-induced signaling: a unique signaling pathway different from prolactin and growth …

T Takeda, H Kurachi, T Yamamoto… - Journal of …, 1997 - joe.bioscientifica.com
The signal transduction mechanism involved in human placental lactogen (hPL) was
studied. We have identified that hPL rapidly stimulated the tyrosine phosphorylation of at …